载脂蛋白L1基因型与尿钾排泄和慢性肾脏病进展的关联
该研究分析1399名自报黑人慢性肾功能不全队列参与者的24小时尿钾和尿钠排泄与APOL1基因型的交互作用。中位随访5.23年,605例发生CKD进展;APOL1基因型与尿钾排泄对CKD进展及CKD进展或死亡存在显著交互作用(P=0.003和P=0.03)。在高危APOL1基因型中,较高尿钾排泄与CKD进展风险降低相关;在低危基因型中则与风险升高相关。
要点
- APOL1基因型与尿钾排泄对CKD进展存在显著交互作用(P=0.003)。
- 高危APOL1基因型中,较高尿钾排泄与CKD进展风险降低相关。
- 低危APOL1基因型中,较高尿钾排泄与CKD进展风险升高相关。
核心结论
- 较高尿钾排泄在高危APOL1基因型中与较低的CKD进展风险相关,在低危APOL1基因型中与较高的CKD进展风险相关。
研究设计与样本
- 研究分析了2003年4月至2008年9月纳入慢性肾功能不全队列的1399名自报黑人参与者。
- 暴露为校准的24小时尿钾和尿钠排泄,主要结局为eGFR下降50%或肾衰竭的CKD进展,次要结局为CKD进展或死亡。
主要发现
- 黑人参与者中位24小时尿钠排泄为150 mmol(四分位距118-188),尿钾排泄为43 mmol(四分位距35-54)。
- 高危和低危APOL1基因型者分别为276例(20%)和1104例(79%)。
- 中位随访5.23年后CKD进展事件为605例,随访7.29年后CKD进展和死亡事件为868例。
- APOL1基因型与尿钾排泄对CKD进展及CKD进展或死亡的交互作用P值分别为0.003和0.03。
- 高危APOL1基因型中,尿钾排泄第2-4四分位相对于第1四分位的CKD进展风险比分别为0.83(95%CI 0.50-1.39)、0.54(95%CI 0.31-0.93)和0.50(95%CI 0.27-0.93)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Progressive CKD in Black individuals is strongly associated with polymorphisms in the APOL1 gene, but it is unknown whether dietary risk factors for CKD progression vary in high- versus low-risk APOL1 genotypes. We investigated if APOL1 genotypes modify associations of dietary potassium and sodium with CKD progression and death. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We analyzed 1399 self-identified Black participants enrolled in the Chronic Renal Insufficiency Cohort from April 2003 to September 2008. Exposures were calibrated 24-hour urine potassium and sodium excretion. The primary outcome was CKD progression defined as the time to 50% decline in eGFR or kidney failure. The secondary outcome was CKD progression or death. We tested for an interaction between urinary potassium and sodium excretion and APOL1 genotypes. RESULTS: Median 24-hour urinary sodium and potassium excretions in Black participants were 150 mmol (interquartile range, 118-188) and 43 mmol (interquartile range, 35-54), respectively. Individuals with high- and low-risk APOL1 genotypes numbered 276 (20%) and 1104 (79%), respectively. After a median follow-up of 5.23 years, CKD progression events equaled 605, and after 7.29 years, CKD progression and death events equaled 868. There was significant interaction between APOL1 genotypes and urinary potassium excretion with CKD progression and CKD progression or death (P=0.003 and P=0.03, respectively). In those with high-risk APOL1 genotypes, higher urinary potassium excretion was associated with a lower risk of CKD progression (quartiles 2-4 versus 1: hazard ratio, 0.83; 95% confidence interval, 0.50 to 1.39; hazard ratio, 0.54; 95% confidence interval, 0.31 to 0.93; and hazard ratio, 0.50; 95% confidence interval, 0.27 to 0.93, respectively). In the low-risk APOL1 genotypes, higher urinary potassium excretion was associated with a higher risk of CKD progression (quartiles 2-4 versus 1: hazard ratio, 1.01; 95% confidence interval, 0.75 to 1.36; hazard ratio, 1.23; 95% confidence interval, 0.91 to 1.66; and hazard ratio, 1.53; 95% confidence interval, 1.12 to 2.09, respectively). We found no interaction between APOL1 genotypes and urinary sodium excretion with CKD outcomes. CONCLUSIONS: Higher urinary potassium excretion was associated with lower versus higher risk of CKD progression in APOL1 high-risk and low-risk genotypes, respectively.
引用
- Ilori TO, Liu J, Rodan AR, et al. Apolipoprotein L1 Genotypes and the Association of Urinary Potassium Excretion with CKD Progression. Clin J Am Soc Nephrol. 2022. PMID: 36400568. doi:10.2215/CJN.02680322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。